BTIG Research Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock Price
BTIG Research has raised its price target for OrthoPediatrics (NASDAQ:KIDS) from $24 to $29, maintaining a "buy" rating and indicating a potential upside of 9.43%. This positive outlook aligns with a consensus "Moderate Buy" rating from analysts, as the company recently exceeded quarterly expectations with a narrower loss per share and higher revenue than anticipated. Several other firms have also adjusted their price targets and ratings for OrthoPediatrics, reflecting a generally optimistic sentiment for the medical device company.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) reported a narrower-than-expected Q2 loss of $0.26 per share, beating the Zacks Consensus Estimate of a $0.31 loss, and also surpassed revenue estimates with $70.51 million against a consensus of $68.03 million. Despite outperforming the market year-to-date, the stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market. Investors are advised to monitor future earnings estimate revisions for further insights.
AIGH Capital Management LLC Takes Position in OrthoPediatrics Corp. $KIDS
AIGH Capital Management LLC has acquired a new position in OrthoPediatrics Corp. (NASDAQ:KIDS), purchasing 269,765 shares valued at approximately $5.16 million, making it their 28th largest holding. OrthoPediatrics recently exceeded analysts' revenue and EPS estimates, reporting $70.51 million in revenue and an adjusted loss of $0.26 per share. Analysts generally maintain a "Moderate Buy" rating for the stock with an average target price of $25.89.
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
OrthoPediatrics (KIDS) reported record revenue and adjusted EBITDA in Q2, with CEO Dave Bailey stating the quarter marked an "inflection point" due to contributions from new products like the 3P Hip System and VerteGlide. The company anticipates continued record performance in H2, driven by strong summer volumes, new product launches, and strategic portfolio expansion including the Veraxis fixation system and growth in specialty bracing. OrthoPediatrics also plans to leverage its strengthened position in Europe and revised operating structures in Latin America to boost international growth and profitability.
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
OrthoPediatrics reported record revenue and adjusted EBITDA in Q2, with CEO Dave Bailey highlighting new "super cycle" products and summer volumes as key drivers. The company anticipates continued growth in the second half of the year, driven by increasing contributions from new hip and spine systems, and expects its specialty bracing business and international markets to further boost performance. OrthoPediatrics is also focusing on capital discipline and strategic partnerships to strengthen its competitive position in pediatric orthopedics.
Wasatch Advisors LP Buys 186,357 Shares of OrthoPediatrics Corp. $KIDS
Wasatch Advisors LP significantly increased its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 56.6% in the second quarter, purchasing an additional 186,357 shares. This brings their total holdings to 515,677 shares, representing 2.01% of the company. OrthoPediatrics recently reported better-than-expected earnings, with a smaller loss per share and higher revenue than anticipated, and analysts currently have a "Moderate Buy" rating on the stock.
Understanding the Setup: (KIDS) and Scalable Risk
This article provides an in-depth analysis of Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a potential long-term breakout if current strong sentiment holds. It offers AI-generated signals, institutional trading strategies tailored to different risk profiles, and a multi-timeframe signal analysis to guide investors. Key findings indicate compelling upside potential with no remaining resistance levels above the current price.
Dimensional Fund Advisors LP Has $8.67 Million Stake in OrthoPediatrics Corp. $KIDS
Dimensional Fund Advisors LP reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 12.2% in the first quarter, though it still holds 546,626 shares valued at $8.67 million. Institutional investors collectively own 69.05% of the stock. Analysts generally maintain a "Moderate Buy" rating for OrthoPediatrics, with an average price target of $25.89, following the company's recent beat on quarterly earnings and revenue expectations.
Orthopediatrics Corp Q2 2026: Revenue $70.5M, EPS $(0.30) — 10-Q Summary
Orthopediatrics Corp (KIDS) reported its Q2 2026 financial results, with revenue increasing to $70.5 million from $61.1 million year-over-year. The company posted a net loss of $7.16 million and diluted EPS of $(0.30), largely consistent with the previous year. Key growth drivers included Trauma & Deformity products, operational expansion in Europe, Canada, and Brazil, and strong product momentum across its portfolio.
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. announced strong financial results for the second quarter of 2026, with revenue surpassing $70 million for the first time, marking a 15% year-over-year increase. The company also reported record adjusted EBITDA of $6.8 million and significantly reduced free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million, expecting continued growth and aiming for cash-flow breakeven in 2026.
OrthoPediatrics Corp. Stock 12‑Month Price Target Raised to $26.67, Implies 28% Upside
Analysts have raised the 12-month average price target for OrthoPediatrics Corp. stock from $25 to $26.67, with individual forecasts ranging from $22 to $35 per share. This new target implies a potential upside of approximately 28% from the Aug. 4 closing price. The consensus rating among 9 covering analysts remains a "Buy," with 8 recommending a Buy and 1 a Hold.
ORTHOPEDIATRICS CORP : NEEDHAM RAISES TARGET PRICE TO $35 FROM $30
Needham has increased its target price for ORTHOPEDIATRICS CORP (KIDS.O) to $35 from the previous $30. This adjustment indicates a more optimistic outlook by the analyst firm regarding the company's future stock performance. The report was issued by Reuters.
OrthoPediatrics (Nasdaq: KIDS) lifts 2026 guidance after strong Q2 growth
OrthoPediatrics reported record Q2 2026 net revenue of $70.5 million, marking a 15% increase year-over-year, primarily driven by strong growth in Trauma and Deformity products and international sales. The company also achieved a record adjusted EBITDA of $6.8 million and significantly improved free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million.
OrthoPediatrics: Q2 Earnings Snapshot
OrthoPediatrics Corp. (KIDS) reported a Q2 loss of $7.2 million, or 30 cents per share, which adjusted to 26 cents per share. The medical device maker posted revenue of $29.5 million for the quarter and expects full-year revenue to be between $125 million and $129 million. This report was generated using data from Zacks Investment Research.
Nearly 46,000 children helped as OrthoPediatrics revenue hits $70.5M
OrthoPediatrics (Nasdaq: KIDS) reported record Q2 2026 revenue of $70.5 million, a 15% year-over-year increase, driven by strong growth in U.S. and international markets, particularly in its Trauma & Deformity segment. The company helped nearly 46,000 children and achieved a record adjusted EBITDA of $6.8 million, leading to an increased full-year 2026 revenue guidance of $265-269 million. Despite a decline in Scoliosis revenue and a net loss of $7.2 million, OrthoPediatrics improved its free cash flow usage significantly and announced a new exclusive distribution agreement with OSSIO for bio-integrative fixation technology.
OrthoPediatrics (NASDAQ: KIDS) eyes $265M–$269M 2026 revenue, cash breakeven
OrthoPediatrics Corp. (NASDAQ: KIDS) is projecting 2026 revenue between $265 million and $269 million, alongside an Adjusted EBITDA of approximately $25 million and roughly breakeven free cash flow. This outlook is detailed in an investor update that also highlights the company's focus on the $6.2 billion global pediatric orthopedic market, its broad product portfolio, and continuous innovation. Despite consistent revenue growth, OrthoPediatrics has continued to post net losses, with diluted EPS at $(1.69) in 2025.
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. announced strong financial results for the second quarter of 2026, with record total revenue of $70.5 million, marking a 15% year-over-year increase, and record adjusted EBITDA of $6.8 million. The company helped nearly 46,000 children and significantly reduced free cash flow usage. Consequently, OrthoPediatrics raised its full-year 2026 revenue guidance to between $265.0 million and $269.0 million.
The Technical Signals Behind (KIDS) That Institutions Follow
This article from Stock Traders Daily discusses the technical signals for Orthopediatrics Corp. (NASDAQ: KIDS) that institutions follow. It highlights strong near-term sentiment with neutral mid and long-term outlooks, noting compelling upside potential due to a lack of resistance levels above the current price. The article also outlines AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
OrthoPediatrics Number of Employees 2026 | Employee Count & Headcount Data
OrthoPediatrics Corp. (NASDAQ: KIDS) has approximately 606 employees worldwide as of March 2026, marking a 13.6% growth from 2023. The company is actively hiring, with 45 active job postings in 2026, an 11.8% increase from 2025. The workforce is primarily concentrated in North America, and the average salary is $102,730.
OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. An audio webcast and replay of the event will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 90 systems for trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 am ET. An audio webcast and replay of the discussion will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering a comprehensive product range across trauma, deformity, scoliosis, and sports medicine.
OrthoPediatrics to Join Canaccord Conference Aug. 12 | KIDS Stock News
OrthoPediatrics (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 9:00 a.m. ET. An audio webcast of the session will be available on the company's investor relations website, with a replay accessible afterwards. Historical data suggests conference participation notices have been followed by negative short-term stock reactions, while substantive product or earnings news has led to positive reactions.
Medical device manufacturer gets a new backbone after global takeover
Chesterfield-based medical device manufacturer SpineCorporation has been acquired by the US healthcare company OrthoPediatrics Corp. The acquisition, supported by Hawsons Corporate Finance and Knights Solicitors, will expand OrthoPediatrics' presence in the specialist healthcare market. This cross-border deal marks a significant milestone for SpineCorporation, with the advisory teams highlighting the increasing activity of international buyers in the healthcare sector.
OrthoPediatrics Corp. Revenue Breakdown – SWB:2X7
OrthoPediatrics Corp. (SWB:2X7) generated €201.23 million in revenue last year, with its Trauma and Deformity segment contributing the most at €141.59 million. The majority of the company's revenue, €158.71 million, originated from the United States. These figures highlight the company's key revenue drivers and geographical performance.
KIDS|OrthoPediatrics Corp|Price:18.840|Chg%:+0.120
OrthoPediatrics Corp (KIDS) has strong fundamentals and high growth potential, with its revenue averaging 58.91% year-on-year growth over the past three years. The stock is considered fairly valued and has a high institutional ownership, with multiple analysts rating it as a "Buy" with a target price of $25.00. Despite recent weak market performance, the company's stock is expected to trend upwards in the medium term.
OrthoPediatrics sets Aug. 4 date for second-quarter results
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after market close. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results, with a live and archived webcast available on its investor relations website. Previous earnings-date announcements for OrthoPediatrics have been followed by positive 24-hour stock reactions.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results. A live and archived webcast will be available on their investor relations website.
OrthoPediatrics to report Q2 2026 financial results on August 4
OrthoPediatrics Corp. is scheduled to release its financial results for the second quarter of 2026 on August 4, 2026, after the market closes. The company, which specializes in pediatric orthopedics, will hold a conference call on the same day at 4:30 p.m. ET to discuss the results. Investors can access the live webcast and a 90-day replay on the Investors page of the company's website.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a webcast available on its Investors page. OrthoPediatrics focuses exclusively on advancing pediatric orthopedics and has a comprehensive product offering distributed globally.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss these results. A webcast of the event will be available on their investor relations website.
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results. Interested parties can access a live and archived webcast of the event on the Investors page of OrthoPediatrics' website.
Precision Trading with Orthopediatrics Corp. (KIDS) Risk Zones
This article analyzes Orthopediatrics Corp. (KIDS) with a focus on precision trading, highlighting a weak near-term sentiment that could lead to bearish positioning. It outlines three distinct AI-generated trading strategies including position, momentum breakout, and risk hedging, tailored for different risk profiles. The analysis also provides multi-timeframe signal analysis and support/resistance levels for various time horizons.
KIDS5867370 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the OrthoPediatrics Corp. bond KIDS5867370, detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.75%, with the next payment anticipated on August 17, 2026. It highlights the importance of understanding bond payment data for investors.
OSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide
OSSIO Inc. has signed an exclusive distribution agreement with OrthoPediatrics Corp. to bring its bio-integrative, metal-free OSSIOfiber® implants to U.S. children's hospitals. This partnership aims to provide an alternative to metal implants for pediatric patients with bone fractures and skeletal deformities, potentially eliminating the need for secondary hardware removal surgeries. The OSSIOfiber implants gradually integrate into the bone, offering stability without leaving permanent foreign material behind.
KIDS5867370 Bond Profile — Key Metrics
This article provides a bond profile for OrthoPediatrics Corp. 4.75% 15-FEB-2030 (KIDS5867370). It details key metrics such as issue date, maturity date, coupon rate, and issuer information. The bond has an outstanding amount of 0.00 USD and a face value of 1,000.00 USD.
OrthoPediatrics Corp. (NASDAQ: KIDS) holders disclose 3.2% ownership stake
Integrated Core Strategies (US) LLC and related Millennium entities, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have reported a beneficial ownership stake of 3.2% in OrthoPediatrics Corp. (NASDAQ: KIDS) through a Schedule 13G/A filing. Integrated Core Strategies holds 811,042 shares, while the Millennium entities and Englander each hold 816,830 shares, all with shared voting and dispositive power. The filing, dated July 14, 2026, confirms that their collective ownership remains below the 5% threshold, indicating a passive investment intent.
OrthoPediatrics (KIDS) Stifel 2024 Healthcare Conference Summary
OrthoPediatrics (KIDS) presented at the Stifel 2024 Healthcare Conference, detailing strong business performance, especially in international scoliosis sales which grew over 100% year-over-year. The company reported that recent stock weakness was due to a fund liquidation, not fundamentals, and highlighted upcoming product innovation like the next-generation RESPONSE system and increased adoption of the 7D navigation system in pediatric spine surgery.
Precision Trading with Orthopediatrics Corp. (KIDS) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Orthopediatrics Corp. (KIDS), highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide precision trading with defined entry, target, and stop-loss zones. The analysis emphasizes institutional-grade insights and risk management.
OrthoPediatrics Corp focuses on pediatric orthopedic growth as KIDS stock tracks sector trends
OrthoPediatrics Corp (KIDS) is a U.S.-based medical device company specializing in orthopedic conditions for children and adolescents, focusing on pediatric-specific implants and instruments. Its business model relies on supplying hospitals and surgical centers with hardware for procedures like deformity correction and fracture stabilization, driven by demographic trends and surgical advancements. The specialization in pediatric orthopedics supports predictable product development and strong relationships with surgeons, while the stock reflects procedure volumes, product launches, and the balance between growth investments and profitability.
OrthoPediatrics | 8-K: OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
This 8-K filing announces that OrthoPediatrics Corp. has reported its financial results for both the fourth quarter and the full year of 2025. This indicates a formal disclosure of the company's financial performance. Investors and analysts would review this document for detailed financial data and future outlook.
Enterprise value to EBITDA forward of OrthoPediatrics Corp. – LSX:A2JAAV
This article provides financial information for OrthoPediatrics Corp. (LSX:A2JAAV) on TradingView, specifically focusing on its enterprise value to EBITDA forward. It indicates market details, including that the market is closed with no current trades.
Price to sales forward of OrthoPediatrics Corp. – NASDAQ:KIDS
This article provides the "Price to sales forward" metric for OrthoPediatrics Corp. (NASDAQ: KIDS) on TradingView. It indicates the stock market, company name, and general financial information availability. The content is brief and contains no specific numerical data or in-depth analysis.
Price to book forward of OrthoPediatrics Corp. – LSX:A2JAAV
The article provides financial information for OrthoPediatrics Corp. (LSX: A2JAAV), specifically focusing on its "Price to book forward" metric. It appears to be a stub or a data-focused page from TradingView, offering a quick overview of this financial ratio for the company.
OrthoPediatrics Corp. Actuals & Estimates (NASDAQ:KIDS)
This article provides an overview of OrthoPediatrics Corp. (NASDAQ:KIDS) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial data such as recent earnings, revenue, and EBITDA, along with information on future earnings report dates. The company's stock volatility, employee count, and dividend policy are also covered.
OrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
OrthoPediatrics Corp. has announced an exclusive distribution agreement with OSSIO, Inc. to bring bio-integrative, metal-free orthopedic fixation technology to U.S. children's hospitals. This technology uses OSSIO fiber implants that are gradually replaced by new bone, reducing the need for secondary hardware removal surgeries common with metal implants in pediatric patients. This partnership enhances OrthoPediatrics' product offerings and aims to address unmet pediatric orthopedic needs while strengthening the company's growth potential.
KIDS Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for OrthoPediatrics Corp. (KIDS), including analyst price targets, past performance, and upcoming earnings dates. It covers key financial metrics like EPS, revenue, market capitalization, net income, and EBITDA, addressing frequently asked questions about the stock.
OrthoPediatrics’ Shift to Sterile Packaging Streamlines Pediatric Implant Care
OrthoPediatrics has converted its IM nail implant portfolio from non-sterile to sterile packaging, redesigning over 1,300 SKUs. This initiative, highlighted at The PACK Out, aims to reduce OR burden, improve hospital workflow, and support scalable growth in pediatric orthopedics. The project successfully decreased packaging complexity from over ten carton sizes to just two by utilizing 3D-printed prototypes and adaptable packaging components.
Orthopediatrics Corp announces a distribution agreement with Ossio, Inc. to introduce revolutionary orthopedic fixation technology to children's hospitals across the United States
Orthopediatrics Corp has signed a distribution agreement with Ossio, Inc. to bring advanced orthopedic fixation technology to children's hospitals across the United States. This collaboration aims to improve surgical outcomes and recovery processes for young patients. The partnership is expected to provide healthcare institutions with more innovative and reliable medical product options in pediatric orthopedics.
OSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide – Ortho Spine News
OSSIO Inc. has signed an exclusive distribution agreement with OrthoPediatrics Corp. to bring its bio-integrative, metal-free OSSIOfiber® implants to children's hospitals across the U.S. These implants are designed to be gradually replaced by the patient's own bone, eliminating the need for a second surgery to remove hardware, which is particularly beneficial for pediatric patients. This partnership aims to accelerate the adoption of this revolutionary orthopedic fixation technology, addressing bone fractures and skeletal deformities in children.
OrthoPediatrics lands metal-free implant deal
OrthoPediatrics Corp. has secured an exclusive distribution agreement with Ossio to introduce metal-free fixation technology to U.S. children's hospitals. The deal involves Ossiofiber implants, which are designed to treat fractures and deformities in pediatric patients and are gradually replaced by new bone, eliminating the need for hardware removal. This bio-integrative solution offers initial fixation strength comparable to metal and fully integrates into bone within 18-24 months.
